Publication | April 19, 2026
Hypoxanthine—early biomarker of outcomes in an ovine model of neonatal hypoxic ischemic encephalopathy
Get the Resource
Read the PaperSapient contributes untargeted metabolomics analysis to a study published in Pediatric Research identifying plasma hypoxanthine as an early predictor of HIE severity.
Hypoxic‑ischemic encephalopathy (HIE) is the leading cause of neonatal morbidity and mortality worldwide, with an alarming 96% of deaths and neurologic disabilities occuring in low- and middle-income countries.
The critical unmet need for HIE remains early-stage diagnostic tools to characterize injury severity, predict outcomes, and guide timely neuroprotective interventions. Clinical signs and imaging findings often emerge after critical therapeutic windows have passed, underscoring the need for early, biologically grounded biomarkers that reflect real‑time metabolic stress and tissue injury.
This study published in Pediatric Research – led by investigators at the University of California, San Francisco (UCSF) and for which Sapient provided mass spectrometry-based untargeted metabolomics analysis – identified a novel correlation between hypoxanthine levels and neurologic impairment severity, highlighting the potential of metabolomics in the early detection of HIE.
For the study, researchers analyzed plasma samples collected at multiple early time points from lambs subjected to hypoxic‑ischemic injury via umbilical cord occlusion, alongside healthy controls and an independent validation cohort. Samples were analyzed via Sapient’s untargeted LC-MS method for broad metabolome profiling, with the goal of identifying metabolic biomarkers of hypoxic-ischemic injury, characterizing their temporal progression, and determining their association with injury severity and neurologic outcomes.
A total of 145 hypoxia biomarkers were identified, showing consistent and reproducible temporal pattern across both discovery and validation cohorts. Hypoxanthine emerged as a key biomarker, with plasma levels measured at 20 minutes of life strongly correlating with neurologic outcome severity. Elevated hypoxanthine reflected early purine metabolism disruption, consistent with hypoxic energy failure and oxidative stress.
While characterizing the temporal dynamics of plasma hypoxanthine, it was found to be an early biomarker showing significant increase within 1 hour following ischemic injury.
These findings contribute to a growing body of evidence supporting the use of hypoxanthine as a potentially clinically useful biomarker following various hypoxic-ischemic states including HIE – and demonstrate the power of untargeted metabolomics analysis as an approach to identifying early biomarkers for prognostication of disease in addition to disease diagnosis.
To learn more, read the full paper and findings.